Lupus & antiphospholipid syndrome
The impact of curcumin supplementation on systemic lupus erythematosus and lupus nephritis: A systematic review
Authors' conclusion
Current data show a potential benefit on disease activity.
Study context
- Population
- Studies assessing the impact of curcumin supplementation on SLE, including lupus nephritis3 RCTs, 3 in vitro, 7 mouse studies
- Comparison
- Curcumin supplementation in SLE
- Outcome
- Efficacy of curcumin on SLE disease activity
Methodological detailsPRISMA
- PRISMA
Pooled result
As reported in the abstract
Human RCTs (14 to 39 patients; 4 to 12 weeks)
- Curcumin decreased 24-h and spot proteinuria
- No change in C3, dsDNA or Systemic Lupus Erythematosus Disease Activity (SLEDAI) scores, even in the longer trials
- Trials small, with varied curcumin doses and study durations
Further pooled results
Mouse-model studies
- 1 mg/kg/day for 14 weeks suppressed NF-κβ activation and inducible nitric oxide synthase (NOS) expression, with significant decreases in dsDNA, proteinuria, renal inflammation and IgG subclasses
- Reduced BAFF at 50 mg/kg/day for up to 8 weeks
- Reduction in Th1 and Th17 percentages, IL-6 and anti-nuclear antibody (ANA) levels
- Murine doses 12.5 mg-200 mg/kg/day, much higher than in human trials
Original publication
The impact of curcumin supplementation on systemic lupus erythematosus and lupus nephritis: A systematic review. Lupus. Published 3 March 2023. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →